{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T21:41:01Z","timestamp":1770759661642,"version":"3.50.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,4]]},"DOI":"10.7759\/cureus.102952","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T12:47:26Z","timestamp":1770209246000},"source":"Crossref","is-referenced-by-count":0,"title":["Anaplastic Lymphoma Kinase (ALK)-Positive Large B-cell Lymphoma in Children: A Case Report and Review of Literature"],"prefix":"10.7759","author":[{"given":"Ryan","family":"Dananjaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes  S","family":"Harahap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teny T","family":"Sari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganda","family":"Ilmana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Novie A","family":"Chozie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda V","family":"Ardhiawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria  F","family":"Ham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1059914","article-title":"The epidemiological patterns of non-Hodgkin lymphoma: global estimates of disease burden, risk factors, and temporal trends","volume":"13","author":"Chu Y","year":"2023","unstructured":"Chu Y, Liu Y, Fang X, et al.. The epidemiological patterns of non-Hodgkin lymphoma: global estimates of disease burden, risk factors, and temporal trends. Front Oncol. 2023, 13:1059914. 10.3389\/fonc.2023.1059914","journal-title":"Front Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-133587","article-title":"Etiologic heterogeneity among non-Hodgkin lymphoma subtypes","volume":"112","author":"Morton LM","year":"2008","unstructured":"Morton LM, Wang SS, Cozen W, et al.. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood. 2008, 112:5150-60. 10.1182\/blood-2008-01-133587","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio R","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, et al.. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022, 36:1720-48. 10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"key":"ref5","article-title":"ALK-positive large B-cell lymphoma","author":"Alaggio R","year":"2022","unstructured":"Alaggio R, Lamant-Rochaix L, d\u2019Amore E, Onciu M, Chan J. ALK-positive large B-cell lymphoma. WHO Classification of Tumours Editorial Board. International Agency for Research on Cancer, Lyon, France; 2022."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2023\/62619.18104","article-title":"ALK-positive Large B-cell lymphoma: a clinicopathologic retrospective descriptive study from a tertiary care cancer centre in India","volume":"17","author":"Vasudevan JA","year":"2023","unstructured":"Vasudevan JA, Nair RA, Jacob PM, Simi C, Prakash N, Mathew A. ALK-positive Large B-cell lymphoma: a clinicopathologic retrospective descriptive study from a tertiary care cancer centre in India. J Clin Diagn Res. 2023, 17:20-4. 10.7860\/JCDR\/2023\/62619.18104","journal-title":"J Clin Diagn Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1941929","article-title":"Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK\u2009+\u2009LBCL): a systematic review of clinicopathological features and management","volume":"62","author":"Castillo JJ","year":"2021","unstructured":"Castillo JJ, Beltran BE, Malpica L, Marques-Piubelli ML, Miranda RN. Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK\u2009+\u2009LBCL): a systematic review of clinicopathological features and management. Leuk Lymphoma. 2021, 62:2845-53. 10.1080\/10428194.2021.1941929","journal-title":"Leuk Lymphoma"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0057","article-title":"NCCN guidelines\u00ae insights: B-cell lymphomas, version 6.2023","volume":"21","author":"Zelenetz AD","year":"2023","unstructured":"Zelenetz AD, Gordon LI, Abramson JS, et al.. NCCN guidelines\u00ae insights: B-cell lymphomas, version 6.2023. J Natl Compr Canc Netw. 2023, 21:1118-31. 10.6004\/jnccn.2023.0057","journal-title":"J Natl Compr Canc Netw"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.16882","article-title":"Anaplastic lymphoma kinase positive large B-cell lymphoma: diagnostic perils and pitfalls, an underrecognized entity","volume":"13","author":"Chowdhury Z","year":"2021","unstructured":"Chowdhury Z. Anaplastic lymphoma kinase positive large B-cell lymphoma: diagnostic perils and pitfalls, an underrecognized entity. Cureus. 2021, 13:e16882. 10.7759\/cureus.16882","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25126447","article-title":"Programmed death ligand 1 (PD-L1) expression in lymphomas: state of the art","volume":"25","author":"Zanelli M","year":"2024","unstructured":"Zanelli M, Fragliasso V, Parente P, et al.. Programmed death ligand 1 (PD-L1) expression in lymphomas: state of the art. Int J Mol Sci. 2024, 25:7. 10.3390\/ijms25126447","journal-title":"Int J Mol Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.08.015","article-title":"Complete response of primary refractory ALK-positive large B-cell lymphoma treated with single-agent nivolumab","volume":"20","author":"Sandoval-Sus JD","year":"2020","unstructured":"Sandoval-Sus JD, Brahim A, Khan A, et al.. Complete response of primary refractory ALK-positive large B-cell lymphoma treated with single-agent nivolumab. Clin Lymphoma Myeloma Leuk. 2020, 20:e113-7. 10.1016\/j.clml.2019.08.015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma","volume":"263","author":"Morris SW","year":"1994","unstructured":"Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994, 263:1281-4. 10.1126\/science.8122112","journal-title":"Science"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19113448","article-title":"Anaplastic lymphoma kinase (ALK) receptor tyrosine kinase: a catalytic receptor with many faces","volume":"19","author":"Huang H","year":"2018","unstructured":"Huang H. Anaplastic lymphoma kinase (ALK) receptor tyrosine kinase: a catalytic receptor with many faces. Int J Mol Sci. 2018, 19:8. 10.3390\/ijms19113448","journal-title":"Int J Mol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030275","article-title":"Targeting ALK in cancer: therapeutic potential of proapoptotic peptides","volume":"11","author":"Aubry A","year":"2019","unstructured":"Aubry A, Galiacy S, Allouche M. Targeting ALK in cancer: therapeutic potential of proapoptotic peptides. Cancers (Basel). 2019, 11:5. 10.3390\/cancers11030275","journal-title":"Cancers (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0776-2","article-title":"Role and targeting of anaplastic lymphoma kinase in cancer","volume":"17","author":"Della Corte CM","year":"2018","unstructured":"Della Corte CM, Viscardi G, Di Liello R, et al.. Role and targeting of anaplastic lymphoma kinase in cancer. Mol Cancer. 2018, 17:30. 10.1186\/s12943-018-0776-2","journal-title":"Mol Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1520099112","article-title":"Augmentor \u03b1 and \u03b2 (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: hierarchy and specificity of ligand-receptor interactions","volume":"112","author":"Reshetnyak AV","year":"2015","unstructured":"Reshetnyak AV, Murray PB, Shi X, et al.. Augmentor \u03b1 and \u03b2 (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: hierarchy and specificity of ligand-receptor interactions. Proc Natl Acad Sci U S A. 2015, 112:15862-7. 10.1073\/pnas.1520099112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.09811","article-title":"FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase","volume":"4","author":"Guan J","year":"2015","unstructured":"Guan J, Umapathy G, Yamazaki Y, et al.. FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase. Elife. 2015, 4:e09811. 10.7554\/eLife.09811","journal-title":"Elife"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00449-x","article-title":"ALK fusions in the pan-cancer setting: another tumor-agnostic target?","volume":"7","author":"Shreenivas A","year":"2023","unstructured":"Shreenivas A, Janku F, Gouda MA, Chen HZ, George B, Kato S, Kurzrock R. ALK fusions in the pan-cancer setting: another tumor-agnostic target?. NPJ Precis Oncol. 2023, 7:101. 10.1038\/s41698-023-00449-x","journal-title":"NPJ Precis Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.5.1483","article-title":"A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation","volume":"89","author":"Delsol G","year":"1997","unstructured":"Delsol G, Lamant L, Mariam\u00e9 B, et al.. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood. 1997, 89:1483-90. 10.1182\/blood.V89.5.1483","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s12308-024-00582-x","article-title":"ALK-positive large B-cell lymphoma (ALK\u2009+\u2009LBCL) with aberrant CD3 expression","volume":"17","author":"Baker J","year":"2024","unstructured":"Baker J, Zadeh SL, Aguilera NS. ALK-positive large B-cell lymphoma (ALK\u2009+\u2009LBCL) with aberrant CD3 expression. J Hematop. 2024, 17:109-14. 10.1007\/s12308-024-00582-x","journal-title":"J Hematop"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000753","article-title":"ALK-positive large B-cell lymphoma: a clinicopathologic study of 26 cases with review of additional 108 cases in the literature","volume":"41","author":"Pan Z","year":"2017","unstructured":"Pan Z, Hu S, Li M, et al.. ALK-positive large B-cell lymphoma: a clinicopathologic study of 26 cases with review of additional 108 cases in the literature. Am J Surg Pathol. 2017, 41:25-38. 10.1097\/PAS.0000000000000753","journal-title":"Am J Surg Pathol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.12936\/tenrikiyo.24-017","article-title":"ALK-positive large B-cell lymphoma showing long-term response to conventional chemoradiotherapy","volume":"100","author":"Ohno H","year":"2021","unstructured":"Ohno H, Takeoka K, Kishimori C, et al.. ALK-positive large B-cell lymphoma showing long-term response to conventional chemoradiotherapy. Tenri Med Bull. 2021, 100:7. 10.12936\/tenrikiyo.24-017","journal-title":"Tenri Med Bull"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178416","article-title":"Anaplastic lymphoma kinase-positive large B-cell lymphoma: clinico-pathological study of 17 cases with review of literature","volume":"12","author":"Jiang XN","year":"2017","unstructured":"Jiang XN, Yu BH, Wang WG, Zhou XY, Li XQ. Anaplastic lymphoma kinase-positive large B-cell lymphoma: clinico-pathological study of 17 cases with review of literature. PLoS One. 2017, 12:e0178416. 10.1371\/journal.pone.0178416","journal-title":"PLoS One"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v9.i17.4268","article-title":"Diagnosis and treatment of pediatric anaplastic lymphoma kinase-positive large B-cell lymphoma: a case report","volume":"9","author":"Zhang M","year":"2021","unstructured":"Zhang M, Jin L, Duan YL, et al.. Diagnosis and treatment of pediatric anaplastic lymphoma kinase-positive large B-cell lymphoma: a case report. World J Clin Cases. 2021, 9:4268-78. 10.12998\/wjcc.v9.i17.4268","journal-title":"World J Clin Cases"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/529572","article-title":"Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma","volume":"2012","author":"Morgan EA","year":"2012","unstructured":"Morgan EA, Nascimento AF. Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma. Adv Hematol. 2012, 2012:529572. 10.1155\/2012\/529572","journal-title":"Adv Hematol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2022.106933","article-title":"Primary appendiceal diffuse large B-cell lymphoma initially presenting as acute appendicitis: a case report","volume":"93","author":"Liu KY","year":"2022","unstructured":"Liu KY, Wu SM, Chen WY, Chang CL. Primary appendiceal diffuse large B-cell lymphoma initially presenting as acute appendicitis: a case report. Int J Surg Case Rep. 2022, 93:106933. 10.1016\/j.ijscr.2022.106933","journal-title":"Int J Surg Case Rep"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2024.05.014","article-title":"ALK-positive large B-cell lymphoma: a clinicopathological and molecular characteristics analysis of seven cases","volume":"56","author":"Wang X","year":"2024","unstructured":"Wang X, Yi H, Liu Q, et al.. ALK-positive large B-cell lymphoma: a clinicopathological and molecular characteristics analysis of seven cases. Pathology. 2024, 56:961-8. 10.1016\/j.pathol.2024.05.014","journal-title":"Pathology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.73","article-title":"ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements","volume":"26","author":"Valera A","year":"2013","unstructured":"Valera A, Colomo L, Mart\u00ednez A, et al.. ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements. Mod Pathol. 2013, 26:1329-37. 10.1038\/modpathol.2013.73","journal-title":"Mod Pathol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4103\/ijmpo.ijmpo_84_16","article-title":"Round Cell Tumors: classification and Immunohistochemistry","volume":"38","author":"Sharma S","year":"2017","unstructured":"Sharma S, Kamala R, Nair D, et al.. Round Cell Tumors: classification and Immunohistochemistry. Indian J Med Paediatr Oncol. 2017, 38:349-53. 10.4103\/ijmpo.ijmpo_84_16","journal-title":"Indian J Med Paediatr Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.37506\/ijfmt.v15i3.15310","article-title":"Round cell tumors - classification overview","volume":"2","author":"Pathak K","year":"2021","unstructured":"Pathak K, Nayak P, Karadwal A, Nayak S, Tekade S. Round cell tumors - classification overview. Indian J Forensic Med Toxicol. 2021, 2:228-39. 10.37506\/ijfmt.v15i3.15310","journal-title":"Indian J Forensic Med Toxicol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.4103\/IJPM.IJPM_1384_20","article-title":"ALK-positive large B-cell lymphomas: a clinicopathologic study","volume":"65","author":"Chandramohan J","year":"2022","unstructured":"Chandramohan J, Ganapule G, Sigamani E, George B, Korula A, Manipadam MT. ALK-positive large B-cell lymphomas: a clinicopathologic study. Indian J Pathol Microbiol. 2022, 65:381-6. 10.4103\/IJPM.IJPM_1384_20","journal-title":"Indian J Pathol Microbiol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2014-0061-RA","article-title":"Immunohistochemistry in undifferentiated neoplasm\/tumor of uncertain origin","volume":"138","author":"Lin F","year":"2014","unstructured":"Lin F, Liu H. Immunohistochemistry in undifferentiated neoplasm\/tumor of uncertain origin. Arch Pathol Lab Med. 2014, 138:1583-610. 10.5858\/arpa.2014-0061-RA","journal-title":"Arch Pathol Lab Med"},{"key":"ref33","article-title":"A practical approach to undifferentiated tumors: a review on helpful markers and common pitfalls","volume":"9","author":"Pradniwat K","year":"2013","unstructured":"Pradniwat K, Treetipsatit J. A practical approach to undifferentiated tumors: a review on helpful markers and common pitfalls. Asian Arch Pathol. 2013, 9:123-36.","journal-title":"Asian Arch Pathol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2022-0459-RA","article-title":"Current approach to undifferentiated neoplasms, with focus on new developments and novel immunohistochemical stains","volume":"147","author":"Borch WR","year":"2023","unstructured":"Borch WR, Monaco SE. Current approach to undifferentiated neoplasms, with focus on new developments and novel immunohistochemical stains. Arch Pathol Lab Med. 2023, 147:1364-73. 10.5858\/arpa.2022-0459-RA","journal-title":"Arch Pathol Lab Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0b013e3181cf1126","article-title":"MUM1\/IRF4: a review","volume":"18","author":"Gualco G","year":"2010","unstructured":"Gualco G, Weiss LM, Bacchi CE. MUM1\/IRF4: a review. Appl Immunohistochem Mol Morphol. 2010, 18:301-10. 10.1097\/PAI.0b013e3181cf1126","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112151-20211117-00836","article-title":"ALK-positive large B-cell lymphoma with EBV infection or cyclin D1 expression: a clinicopathological analysis of 3 cases","volume":"51","author":"Wu WN","year":"2022","unstructured":"Wu WN, Xiang CX, Ma DS, Liu GZ, Liu H. ALK-positive large B-cell lymphoma with EBV infection or cyclin D1 expression: a clinicopathological analysis of 3 cases. Zhonghua Bing Li Xue Za Zhi. 2022, 51:506-11. 10.3760\/cma.j.cn112151-20211117-00836","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0163-z","article-title":"Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients","volume":"8","author":"Loghavi S","year":"2015","unstructured":"Loghavi S, Alayed K, Aladily TN, et al.. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients. J Hematol Oncol. 2015, 8:65. 10.1186\/s13045-015-0163-z","journal-title":"J Hematol Oncol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10121019","article-title":"Hodgkin Reed-Sternberg-like cells in non-Hodgkin lymphoma","volume":"10","author":"Parente P","year":"2020","unstructured":"Parente P, Zanelli M, Sanguedolce F, Mastracci L, Graziano P. Hodgkin Reed-Sternberg-like cells in non-Hodgkin lymphoma. Diagnostics (Basel). 2020, 10:9. 10.3390\/diagnostics10121019","journal-title":"Diagnostics (Basel)"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015443","article-title":"Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma","volume":"140","author":"Soumerai JD","year":"2022","unstructured":"Soumerai JD, Rosenthal A, Harkins S, et al.. Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma. Blood. 2022, 140:1822-6. 10.1182\/blood.2022015443","journal-title":"Blood"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1285374","article-title":"Anaplastic lymphoma kinase inhibitors\u2014a review of anticancer properties, clinical efficacy, and resistance mechanisms","volume":"14","author":"Kie\u0142bowski K","year":"2023","unstructured":"Kie\u0142bowski K, \u017bychowska J, Becht R. Anaplastic lymphoma kinase inhibitors\u2014a review of anticancer properties, clinical efficacy, and resistance mechanisms. Front Pharmacol. 2023, 14:4. 10.3389\/fphar.2023.1285374","journal-title":"Front Pharmacol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27875","article-title":"Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach","volume":"12","author":"Carcereny E","year":"2021","unstructured":"Carcereny E, Fern\u00e1ndez-Nistal A, L\u00f3pez A, et al.. Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach. Oncotarget. 2021, 12:316-32. 10.18632\/oncotarget.27875","journal-title":"Oncotarget"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12240","article-title":"Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response","volume":"92","author":"Wass M","year":"2014","unstructured":"Wass M, Behlendorf T, Sch\u00e4dlich B, Mottok A, Rosenwald A, Schmoll HJ, Jordan K. Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response. Eur J Haematol. 2014, 92:268-70. 10.1111\/ejh.12240","journal-title":"Eur J Haematol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2023.2271212","article-title":"Acquired resistance to crizotinib in novel CDK14-ALK and CLTC-ALK fusions of ALK-positive large B-cell lymphoma identified by next-generation sequencing","volume":"24","author":"Xia Y","year":"2023","unstructured":"Xia Y, Zhang L, He W, Pan H, Fang J, Cui G. Acquired resistance to crizotinib in novel CDK14-ALK and CLTC-ALK fusions of ALK-positive large B-cell lymphoma identified by next-generation sequencing. Cancer Biol Ther. 2023, 24:2271212. 10.1080\/15384047.2023.2271212","journal-title":"Cancer Biol Ther"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14671","article-title":"Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: an open-label phase II trial","volume":"111","author":"Fukano R","year":"2020","unstructured":"Fukano R, Mori T, Sekimizu M, et al.. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: an open-label phase II trial. Cancer Sci. 2020, 111:4540-7. 10.1111\/cas.14671","journal-title":"Cancer Sci"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1480880","article-title":"Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review","volume":"14","author":"Wang H","year":"2024","unstructured":"Wang H, Bai J, Zhang B, et al.. Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review. Front Oncol. 2024, 14:1480880. 10.3389\/fonc.2024.1480880","journal-title":"Front Oncol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-011-0049-z","article-title":"Serum neuron-specific enolase is correlated with clinical outcome of patients with non-germinal center B cell-like subtype of diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy","volume":"29","author":"Wang L","year":"2012","unstructured":"Wang L, Liu P, Chen X, Geng Q, Lu Y. Serum neuron-specific enolase is correlated with clinical outcome of patients with non-germinal center B cell-like subtype of diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy. Med Oncol. 2012, 29:2153-8. 10.1007\/s12032-011-0049-z","journal-title":"Med Oncol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113986","article-title":"Prognostic significance of neuron-specific enolase in patients with malignant lymphoma","volume":"29","author":"Mizuno K","year":"2018","unstructured":"Mizuno K, Ogura S, Kamiya T, et al.. Prognostic significance of neuron-specific enolase in patients with malignant lymphoma. Blood. 2018, 29:1708. 10.1182\/blood-2018-99-113986","journal-title":"Blood"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S203010","article-title":"NSE from diffuse large B-cell lymphoma cells regulates macrophage polarization","volume":"11","author":"Zhu MY","year":"2019","unstructured":"Zhu MY, Liu WJ, Wang H, Wang WD, Liu NW, Lu Y. NSE from diffuse large B-cell lymphoma cells regulates macrophage polarization. Cancer Manag Res. 2019, 11:4577-95. 10.2147\/CMAR.S203010","journal-title":"Cancer Manag Res"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-1934-1","article-title":"ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern","volume":"103","author":"Sakamoto K","year":"2016","unstructured":"Sakamoto K, Nakasone H, Togashi Y, et al.. ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern. Int J Hematol. 2016, 103:399-408. 10.1007\/s12185-016-1934-1","journal-title":"Int J Hematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/446396-anaplastic-lymphoma-kinase-alk-positive-large-b-cell-lymphoma-in-children-a-case-report-and-review-of-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T12:47:27Z","timestamp":1770209247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/446396-anaplastic-lymphoma-kinase-alk-positive-large-b-cell-lymphoma-in-children-a-case-report-and-review-of-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":49,"URL":"https:\/\/doi.org\/10.7759\/cureus.102952","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,4]]}}}